002022.SZ लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 12:34):

Stats
आज की मात्रा	3.46M
औसत मात्रा	6.40M
बाजार मूल्य	3.81B
EPS	CNY-0.0798 ( 2023-09-30 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-12.16
ATR14	CNY0.00700 (0.09%)

मात्रा सहसंबंध

लंबा: 0.04 (neutral)

छोटा: 0.00 (neutral)

Signal:(57.351) Neutral

Shanghai Kehua सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Shanghai Kehua सहसंबंध - मुद्रा/वस्त्र

-0.12
( neutral )

0.22
( neutral )

0.00
( neutral )

0.09
( neutral )

Shanghai Kehua वित्तीय

Annual	2023
राजस्व:	CNY2.41B
सकल लाभ:	CNY891.03M (36.92 %)
EPS:	CNY-0.460

FY	2023
राजस्व:	CNY2.41B
सकल लाभ:	CNY891.03M (36.92 %)
EPS:	CNY-0.460

FY	2022
राजस्व:	CNY6.97B
सकल लाभ:	CNY3.66B (52.56 %)
EPS:	CNY3.37

FY	2021
राजस्व:	CNY4.27B
सकल लाभ:	CNY2.32B (54.46 %)
EPS:	CNY1.403

Financial Reports:

No articles found.

Shanghai Kehua

Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.